Braidwell’s Candel Therapeutics CADL Stock Holding History

Braidwell’s Portfolio CADL Stock Details CADL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-1,600,000	Closed	-$13.9M	–	68
2024 Q4	$13.9M	Buy	+1,600,000	New	+$9.45M	0.41%	60

Other funds holding CADL

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

ACA

Acorn Capital Advisors New York $366M AUM 474.6% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

PCM

Portolan Capital Management Boston, Massachusetts $2.67B AUM 169.09% 1-Year Est. Return

HFF

Halter Ferguson Financial Carmel, Indiana $617M AUM 69.99% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

SCV

Sands Capital Ventures Arlington, Virginia $614M AUM 19.92% 1-Year Est. Return

Braidwell's CADL Position: Q1 2025 in Review

Braidwell sold out of Candel Therapeutics (CADL) in Q1 2025, closing a stake of 1,600,000 shares — an estimated $13.9M sold.

Braidwell first reported a position in CADL in Q4 2024 and held it in 1 quarter. The position peaked at $13.9M in Q4 2024. 82 funds tracked by Wall St. Rank hold CADL as of Q1 2025.

Braidwell reported no remaining Candel Therapeutics position as of Q1 2025 after selling out during the quarter.
Braidwell sold 1,600,000 Candel Therapeutics shares in Q1 2025, an estimated $13.9M.
Braidwell first reported a position in Candel Therapeutics in Q4 2024 and held it in 1 quarter.
Braidwell's Candel Therapeutics position peaked at $13.9M in Q4 2024.
82 funds tracked by Wall St. Rank held Candel Therapeutics as of Q1 2025.

Based on Braidwell's 13F filing for Q1 2025, filed 15 May 2025.